Event Type
Disclosure
Voluntary
Variant
8-K
of this Current Report (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a
Other Events. On January 6, 2026, the Company provided a corporate update and highlighted key milestones and expected momentum in the azenosertib development pr
Financial Statements and Exhibits. (d) Exhibits The following Exhibit 99.1 relating to Item 7.01 shall be deemed to be furnished, and not filed: Exhibit No. Des